| Medical and Health Sciences | Lifetime | 147 | US 82 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 166 | US 61 | 99.97 |
| Pulmonary and Respiratory Medicine | Lifetime | 5 | US 4 | 99.99 |
| Surgery | Lifetime | 115 | US 60 | 99.90 |
| Cancer Research | Lifetime | 73 | US 45 | 99.63 |
| Oncology | Lifetime | 252 | US 143 | 99.59 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 11 | US 4 | 99.96 |
| Oncology | 2021-2025 | 128 | US 54 | 99.14 |
| Cancer Research | 2021-2025 | 74 | US 29 | 96.72 |
| Econometrics and Quantitative Economics | 2021-2025 | 726 | US 188 | 95.53 |
| Molecular Biology | 2021-2025 | 969 | US 268 | 94.48 |
| Renal and related cancers | Lifetime | 1 | US 1 | 99.96 |
| Renal cell carcinoma treatment | Lifetime | 1 | US 1 | 99.98 |
| Cancer Genomics and Diagnostics | Lifetime | 4 | US 4 | 99.97 |
| Testicular diseases and treatments | Lifetime | 1 | US 1 | 99.94 |
| Economic and Financial Impacts of Cancer | Lifetime | 3 | US 3 | 99.94 |
| Ferroptosis and cancer prognosis | Lifetime | 8 | US 4 | 99.71 |
| Neuroblastoma Research and Treatments | Lifetime | 7 | US 7 | 99.80 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 24 | US 14 | 99.93 |
| Multiple and Secondary Primary Cancers | Lifetime | 7 | US 2 | 99.84 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 39 | US 26 | 99.83 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 57 | US 39 | 99.65 |
| Ovarian cancer diagnosis and treatment | Lifetime | 139 | US 77 | 99.29 |
| Sarcoma Diagnosis and Treatment | Lifetime | 217 | US 115 | 99.02 |
| Cancer Diagnosis and Treatment | Lifetime | 195 | US 106 | 98.72 |
| Cancer therapeutics and mechanisms | Lifetime | 245 | US 148 | 98.59 |
| Urologic and reproductive health conditions | Lifetime | 192 | US 108 | 98.77 |
| Cancer Research and Treatments | Lifetime | 529 | US 300 | 97.29 |
| Renal Diseases and Glomerulopathies | Lifetime | 657 | US 232 | 97.16 |
| Sexual Differentiation and Disorders | Lifetime | 453 | US 187 | 96.55 |
| Multiple Myeloma Research and Treatments | Lifetime | 806 | US 357 | 96.20 |
| Gestational Trophoblastic Disease Studies | Lifetime | 139 | US 63 | 94.99 |
| Tuberous Sclerosis Complex Research | Lifetime | 178 | US 103 | 92.60 |
| Cancer Genomics and Diagnostics | 2021-2025 | 8 | US 4 | 99.91 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 2 | US 2 | 99.79 |
| Renal and related cancers | 2021-2025 | 2 | US 2 | 99.94 |
| Renal cell carcinoma treatment | 2021-2025 | 2 | US 2 | 99.94 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 19 | US 4 | 99.90 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 60 | US 19 | 99.23 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 32 | US 15 | 99.46 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 10 | US 6 | 98.21 |
| Ferroptosis and cancer prognosis | 2021-2025 | 497 | US 44 | 93.60 |
